eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
11/10/20
Eyenovia Reports Third Quarter 2020 Financial Results
11/05/20
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
10/12/20
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
Upcoming Events
There are currently no events scheduled.